IL295427A - A method to reduce beta amyloid monomer levels in patients with cognitive decline - Google Patents
A method to reduce beta amyloid monomer levels in patients with cognitive declineInfo
- Publication number
- IL295427A IL295427A IL295427A IL29542722A IL295427A IL 295427 A IL295427 A IL 295427A IL 295427 A IL295427 A IL 295427A IL 29542722 A IL29542722 A IL 29542722A IL 295427 A IL295427 A IL 295427A
- Authority
- IL
- Israel
- Prior art keywords
- subject
- amyloid
- months
- effective amount
- therapeutically effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976325P | 2020-02-13 | 2020-02-13 | |
| PCT/US2021/018023 WO2021163613A1 (en) | 2020-02-13 | 2021-02-12 | Method of decreasing amyloid beta monomer levels in patients with cognitive decline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL295427A true IL295427A (en) | 2022-10-01 |
Family
ID=77292728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295427A IL295427A (en) | 2020-02-13 | 2021-02-12 | A method to reduce beta amyloid monomer levels in patients with cognitive decline |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230098944A1 (https=) |
| EP (1) | EP4103604A4 (https=) |
| JP (2) | JP2023513220A (https=) |
| KR (1) | KR20220142477A (https=) |
| CN (1) | CN115397849A (https=) |
| AU (1) | AU2021218735A1 (https=) |
| IL (1) | IL295427A (https=) |
| WO (1) | WO2021163613A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2692258C2 (ru) | 2014-01-31 | 2019-06-24 | Когнишн Терапьютикс, Инк. | Композиции изоиндолина и способы лечения нейродегенеративного заболевания |
| WO2024196799A2 (en) * | 2023-03-17 | 2024-09-26 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| CN117945980A (zh) * | 2024-01-24 | 2024-04-30 | 上海健康医学院 | 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用 |
| WO2026030341A1 (en) * | 2024-07-29 | 2026-02-05 | Cognition Therapeutics, Inc. | Zervimesine for treating neurodegenerative disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1753662A (zh) * | 2002-12-24 | 2006-03-29 | 神经化学（国际）有限公司 | 用于治疗β－淀粉状蛋白相关疾病的治疗制剂 |
| CA2611586A1 (en) * | 2005-04-12 | 2007-06-21 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| RU2692258C2 (ru) * | 2014-01-31 | 2019-06-24 | Когнишн Терапьютикс, Инк. | Композиции изоиндолина и способы лечения нейродегенеративного заболевания |
| WO2018156883A1 (en) * | 2017-02-23 | 2018-08-30 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| WO2019089988A1 (en) * | 2017-11-01 | 2019-05-09 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| AU2019318888A1 (en) * | 2018-08-07 | 2021-03-18 | Sumitomo Pharma Co., Ltd. | Diagnostic drug and diagnostic method for alzheimer's disease |
-
2021
- 2021-02-12 AU AU2021218735A patent/AU2021218735A1/en active Pending
- 2021-02-12 US US17/798,667 patent/US20230098944A1/en active Pending
- 2021-02-12 KR KR1020227031662A patent/KR20220142477A/ko active Pending
- 2021-02-12 CN CN202180027929.1A patent/CN115397849A/zh active Pending
- 2021-02-12 EP EP21754581.3A patent/EP4103604A4/en active Pending
- 2021-02-12 WO PCT/US2021/018023 patent/WO2021163613A1/en not_active Ceased
- 2021-02-12 JP JP2022548088A patent/JP2023513220A/ja active Pending
- 2021-02-12 IL IL295427A patent/IL295427A/en unknown
-
2025
- 2025-11-24 JP JP2025202377A patent/JP2026041805A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115397849A (zh) | 2022-11-25 |
| US20230098944A1 (en) | 2023-03-30 |
| JP2026041805A (ja) | 2026-03-10 |
| WO2021163613A1 (en) | 2021-08-19 |
| JP2023513220A (ja) | 2023-03-30 |
| EP4103604A1 (en) | 2022-12-21 |
| AU2021218735A1 (en) | 2022-09-01 |
| KR20220142477A (ko) | 2022-10-21 |
| EP4103604A4 (en) | 2024-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295427A (en) | A method to reduce beta amyloid monomer levels in patients with cognitive decline | |
| US20180325862A1 (en) | Methods for treating alzheimer?s disease and related disorders | |
| US12594255B2 (en) | Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement | |
| US9579315B2 (en) | Methods of treating obstructive lung diseases using bitter tastants | |
| CA3154744A1 (en) | Glp-1 receptor agonists in dementia | |
| CN110248650A (zh) | 用于增强突触发生和神经突发生的方法 | |
| JP2021523126A (ja) | 蓄積した病理学的Ｔａｕタンパク質を低減する方法 | |
| RU2841658C1 (ru) | Способ снижения уровней мономеров бета-амилоида у пациентов со снижением когнитивных способностей | |
| CN104780917B (zh) | 基于巴氯芬和阿坎酸的黄斑变性病症的疗法 | |
| HK40083593A (en) | Method of decreasing amyloid beta monomer levels in patients with cognitive decline | |
| CN115052595B (zh) | 用于治疗神经学疾病或病症的新型治疗方法 | |
| CN119055674B (zh) | 一种可改善认知的组合物及其在阿尔茨海默病防治中的应用 | |
| Ueda et al. | Perampanel Blocks Transsynaptic α‐Synuclein Propagation and Neurodegeneration in a Mouse Model of Lewy Body Disease | |
| US10092612B2 (en) | Garcinia mangostana composition, medication and health food including the same | |
| Heale | Alterations in autophagy marker distribution in different genetic subtypes of frontotemporal lobar degeneration | |
| WO2025221208A1 (en) | Use of mitoxantrone hydrochloride as a therapeutic drug for treating neurodegenerative disorders | |
| EP4661859A1 (en) | Oral phenylbutyrate for treatment of human 4-repeat tauopathies | |
| JP2025510556A (ja) | アルツハイマー型認知症に罹患している患者の治療において使用するためのスフィンゴシン－１－リン酸受容体（ｓ１ｐｒ）モジュレーター | |
| CN120459095A (zh) | 氨基吡啶类物质抑制α-突触核蛋白聚集和路易小体形成的用途 | |
| US20190307833A1 (en) | Treatment of age-related macular degeneration with neurotrophic peptidergic compound | |
| JP2026502145A (ja) | プリオン病に対する治療化合物としてのウロポルフィリンｉ | |
| Killinger | Axonal Transport, Parkin, And Α-Synuclein; Novel Therapeutic Targets To Treat Methamphetamine Neurotoxicity | |
| EP3648794A1 (en) | Use of macroazapyridinophanes metal complexes in the treatment of diseases | |
| Soheili et al. | Aqueous extract of lavender (Lavandula angustifolia) improves the spatial performance of a rat model of Alzheimer’s disease | |
| HK40021759B (zh) | 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途 |